君实生物2025年净亏损8.74亿元

Core Viewpoint - Junshi Biosciences reported a significant increase in total revenue for 2025, driven primarily by the strong sales performance of its core product, Toripalimab injection (brand name: Tuoyi®) in the domestic market [1] Financial Performance - The total revenue for 2025 reached 2.498 billion yuan, representing a year-on-year growth of 28.23% [1] - The net loss attributable to the parent company was 874 million yuan, an improvement from a loss of 1.281 billion yuan in the previous year [1] Product Performance - The increase in revenue was mainly due to the substantial growth in sales of Toripalimab injection in the domestic market [1]